Intracranial anti-tumor activity of lazertinib in patients with advanced NSCLC who progressed after prior EGFR TKI therapy: Data from a phase I/II study.

Sang‐We Kim, Myung‐Ju Ahn, Ji‐Youn Han, Ki Hyeong Lee, Eun Kyung Cho, Yun‐Gyoo Lee, Dong‐Wan Kim, Joo-Hang Kim, Jong‐Seok Lee, Gyeong‐Won Lee, Byoung Yong Shim, Jin-Soo Kim, Sang Hoon Chun, Sung Sook Lee, Young Joo Min, Sang Won Shin, Young Ju Lee, Dae Ho Lee, Hana Lee, Byoung Chul ChoJournal of Clinical Oncology 2020 · DOI

Abstract

9571 Background: Lazertinib (YH25448) is a highly mutant-selective, irreversible 3 rd -generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets the activating EGFR mutations (Del19 and L858R), as well as the T790M mutation, while sparing wild type. Brain metastasis (BM) are common in patients (pts) with advanced NSCLC. Lazertinib showed a high blood-brain barrier penetration profile in preclinical studies. We report intracranial response data in pts with advanced NSCLC from a Phase I/II study of lazertinib (NCT03046992). Methods: Pts with advanced NSCLC, who had progressed after prior EGFR-TKI therapy, were enrolled in an open-label, multicenter, phase I/II study with dose-escalation, dose-expansion and dose-extension phases. Brain MRI was done in all pts at baseline. Pts with asymptomatic BM were eligible for enrollment. Intracranial anti-tumor activity of lazertinib was analysed in pts with BM present on baseline brain scan. Pre-defined intracranial endpoints included objective intracranial response rate (OIRR) and intracranial progression-free survival (IPFS) by independent central review (ICR). The brain metastasis full analysis population included pts with measurable and/or non-measurable BM lesion present on baseline brain scan; the brain metastasis population evaluable for response included only pts with measurable BM lesion. Results: As of 30 Sep 2019, a total of 181 pts received at least one dose of lazertinib 20-320 mg across 7 dose levels. Of those, 64 pts (56% female, median age 63, 86% T790M mutation positive by central testing) were included in the brain metastasis full analysis population; Intracranial disease control rate (IDCR) was 90.6% (58/64; 95% CI 83.5, 97.8) and median IPFS was not reached (95% CI 14.0, NR). In the brain metastasis population evaluable for response, a total of 22 pts were included; OIRR and IDCR were 54.5% (12/22; 95% CI 33.7, 75.4) and 90.9% (20/22; 95% CI 78.9, 100), respectively. In 13 pts (7.2%) out of 181 pts, brain was the first site of disease progression by existing and/or new lesions. Conclusions: Lazertinib demonstrated clinically meaningful activity against BM, aligned with preclinical data. Clinical trial information: NCT03046992 .
BibTeX
@article{kim2020intracranial,
  author = {Sang‐We Kim and Myung‐Ju Ahn and Ji‐Youn Han and Ki Hyeong Lee and Eun Kyung Cho and Yun‐Gyoo Lee and Dong‐Wan Kim and Joo-Hang Kim and Jong‐Seok Lee and Gyeong‐Won Lee and Byoung Yong Shim and Jin-Soo Kim and Sang Hoon Chun and Sung Sook Lee and Young Joo Min and Sang Won Shin and Young Ju Lee and Dae Ho Lee and Hana Lee and Byoung Chul Cho},
  title = {{Intracranial anti-tumor activity of lazertinib in patients with advanced NSCLC who progressed after prior EGFR TKI therapy: Data from a phase I/II study.}},
  journal = {Journal of Clinical Oncology},
  year = {2020},
  doi = {10.1200/jco.2020.38.15\_suppl.9571},
}

Loading related content...

Figure